Skip to content

VisionApp - Ghosting

Assessment of the Accuracy and Repeatability of the VisionApp - Ghosting Measurement Protocol

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07571538
Enrollment
12
Registered
2026-05-06
Start date
2025-10-10
Completion date
2026-12-01
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diplopia, Monocular

Brief summary

Recent Android mobile device technology is available which allows user-measured refractive error and reading add power. This technology could be quite useful to the clinical and research community. The current study aims to evaluate the accuracy, repeatability, and reproducibility of one such technology by VisionApp, specifically with regard to ghosting vision. VisionApp is an app which runs on a smartphone or other device which uses the distance between the user's face and the phone to determine refractive error, while the user looks at different targets (lines, letters, words, etc).

Detailed description

Subjects will be enrolled at the Clinical Optics Research Lab at Indiana University. At the study visit, demographic and health/ocular history may be collected by oral history and standard clinical testing including refraction (check of glasses prescription), auto-refraction or abbrerometry may be performed. Visual acuity and room lighting checks may also be measured using standard clinical techniques. For the experimental portion of the study visit, participants will be asked to look at letters and describe any shadows or distortions they see using slider bars or numerical rating scales, while wearing different contact lenses. Participants will first be asked to wear commercially available single vision contact lenses to establish best corrected vision. A single vision lens will then remain in one eye, and participants will proceed with ghosting assessments using two different multifocal contact lenses worn in the other eye. Adult participants will perform the ghosting assessments while wearing 2 commercially available multifocal lenses, and children participants will perform the ghosting assessments while wearing a commercially available and investigational lens. Randomization will determine which lens is worn first. If participants are unable to complete all testing in a single session, they may be permitted to return on a subsequent day.

Interventions

DEVICEProclear 1 Day Contact Lens

Proclear 1 day is a commercially available single vision soft contact lens for single use (daily wear). Participants will wear these contacts at the beginning of the study visit to establish best corrected vision. Participants will then continue to wear this contact lens in one eye for the duration of the study visit.

DEVICEMyDay Contact Lens

MyDay is a commercially available multifocal soft contact lens for daily wear. Adult participants will assess images for ghosting while wearing a MyDay contact lens in one eye. Order of exposure to this lens will be determined via randomization.

DEVICENaturalVue Contact Lens

NaturalVue is a commercially available multifocal soft contact lens for daily wear. Adult participants will assess images for ghosting while wearing a NaturalVue contact lens in one eye. Order of exposure to this lens will be determined via randomization.

MiSight 1 Day is a commercially available multifocal soft contact lens for daily wear. Children participants will assess images for ghosting while wearing a MiSight 1 Day contact lens in one eye. Order of exposure to this lens will be determined via randomization.

An investigational multifocal soft contact lens for daily wear. While the contact lens is made of an FDA approved material which is already marketed in the United States, it differs from commercially available lenses in that it has a slightly different optical design. Children participants will assess images for ghosting while wearing this investigational contact lens in one eye. Order of exposure to this lens will be determined via randomization.

DEVICEVisionApp

VisionApp is an app which runs on a smartphone or other device which uses the distance between the user's face and the phone to determine refractive error, while the user looks at different targets (lines, letters, words, etc.)

Sponsors

Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* has a refractive error between Plano and -5.00 D of sphere and cylinder components combined. * has refractive cylinder (e.g., astigmatism) of -0.75 D or less * has had a self-reported oculo-visual exam in the last 2 years * has best-corrected visual acuity of at least 20/20 in each eye * is not amblyopic or does not have any diagnosed ocular disease * is willing and able to follow instructions and maintain the appointment schedule

Exclusion criteria

* has any systemic disease affecting ocular health and visual acuity * is currently using any systemic or topical medications that could affect ocular health and visual acuity * is participating in another eye related research study

Design outcomes

Primary

MeasureTime frameDescription
Ghosting QuantificationDay 1Ghosting quantification (e.g. how "doubled" the image looks) will be compared against expected template images and those predicted. Subjects will provide a quality rating of ghosting on a scale between 0 - 100, with lower scores indicating more ghosting of the image and 100 representing an optically perfect image. The VisionApp will also model ghosting measurements for direction, separation, blur and strength into a predictive quality rating, which will be compared to the subject's subjective expected, or overall, quality rating.

Countries

United States

Contacts

CONTACTPete Kollbaum, PhD
kollbaum@iu.edu812-555-5500

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 25, 2026